This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2025 Apr 10;145(15):1595-1596.

doi: 10.1182/blood.2024027932.

Daratumumab: a game changer in early myeloma

María-Victoria Mateos^{1

2

3

4}, Verónica González-Calle^{1

2

3}

Affiliations

Affiliations

¹ University Hospital of Salamanca.
² Institute for Biomedical Research of Salamanca.
³ Institute of Cancer Molecular and Cellular Biology.
⁴ University of Salamanca.

PMID: 40208649
DOI: 10.1182/blood.2024027932

Editorial

Daratumumab: a game changer in early myeloma

María-Victoria Mateos et al. Blood. 2025.

. 2025 Apr 10;145(15):1595-1596.

doi: 10.1182/blood.2024027932.

Authors

María-Victoria Mateos^{1

2

3

4}, Verónica González-Calle^{1

2

3}

Affiliations

¹ University Hospital of Salamanca.
² Institute for Biomedical Research of Salamanca.
³ Institute of Cancer Molecular and Cellular Biology.
⁴ University of Salamanca.

PMID: 40208649
DOI: 10.1182/blood.2024027932

No abstract available

PubMed Disclaimer

Comment on

Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUS.
Landgren O, Chari A, Cohen YC, Spencer A, Voorhees PM, Sandhu I, Jenner MW, Smith D, Cavo M, van de Donk NWCJ, Beksac M, Moreau P, Goldschmidt H, Vieyra D, Sha L, Li L, Rousseau E, Dennis R, Carson R, Hofmeister CC. Landgren O, et al. Blood. 2025 Apr 10;145(15):1658-1669. doi: 10.1182/blood.2024025897. Blood. 2025. PMID: 39652826 Clinical Trial.

Publication types

Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Silverchair Information Systems